RedHill Biopharma (RDHL) Tops Q1 Loss Views

RedHill Biopharma (NASDAQ: RDHL) reported Q1 EPS of ($0.06), $0.52 better than the analyst estimate of ($0.58).

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• Trump discloses over $1.4 billion in crypto income in 2025 filing
• FactSet (FDS) Tops Q3 EPS by 8c ; Offers Guidance
• General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance